DAX+0,55 % EUR/USD-0,27 % Gold+0,16 % Öl (Brent)-0,32 %

Thema: CRC Thema abonieren

Nachrichten zu "CRC"

11.11.2019
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma
...mCRC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated hypophysitis occurred in 3.4% (4/119) of patients. In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994) of patients. In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg, adrenal insufficiency occurred in 5% (21/407) of patients. In RCC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, adrenal insufficiency occurred in 7% (41/547) of patients. In MSI-H/dMMR mCRC patients... [mehr]
(
0
Bewertungen)
08.11.2019
Colony Capital Announces Third Quarter 2019 Financial Results and Strategic Asset Review Update
...quarter 2019, the Company’s energy investment management arm, Alpine Energy Capital (formerly known as Colony HB2 Energy) formed a strategic joint venture with California Resources Corporation (NYSE: CRC), to which Alpine has committed to fund $320 million for the development of CRC’s flagship Elk Hills field. Alpine is a joint venture between the Company and Sam Zell’s Equity Group Investments, led by Alpine’s seasoned management team, including Chairman Craig Perry and Chief... [mehr]
(
0
Bewertungen)
07.11.2019
Ultivue erweitert UltiMapper-Portfolio von Multiplex-Marker-Assays für umfassende Phänotypisierung der Immun-Mikroumgebungs- und Gewebe-Immunprofilierungs- Forschung
...Profiling T-reg and CTL relationships in the TME of NSCLC FFPE samples (Profilierung der T-reg- und CTL-Beziehungen in der Tumormikroumgebung von NSCLC FFPE-Proben) P567: Characterizing MDSCs in the TME of CRC FFPE samples (Charakterisierung von MDSCs in der Tumormikroumgebung von CRC FFPE-Proben) Samstag, 9. November, 7 bis 20.30 Uhr: P40: Tumor immunity signatures to expand current Dx approaches in MMR-deficient cancers in the context of Lynch Syndrome through ISP technology and Tissue... [mehr]
(
0
Bewertungen)
05.11.2019
Liberty Latin America Reports Q3 and YTD 2019 Results
...(1.8 %)   (1.8 %) Cabletica CRC 24,211     —    ... [mehr]
(
0
Bewertungen)
31.10.2019
California Resources Corporation Announces Third Quarter 2019 Results
...capital invested during the quarter of 2019 was $188 million, within our guidance. CRC internally funded $117 million, of which $101 million was directed to drilling and capital workovers. CRC's JV partner Benefit Street Partners (BSP) also invested $5 million, which is included in CRC's consolidated results. CRC's JV partners Macquarie Infrastructure and Real Assets Inc. (MIRA) and Alpine Energy Capital, LLC (Alpine) invested an additional $3 million and $63 million, respectively, which are... [mehr]
(
0
Bewertungen)
DGAP-News22.07.2013
Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
...CRC screening could save lives and be health-economically beneficial 22.07.2013 / 10:30 --------------------------------------------------------------------- Press release Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial - CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates - Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC... [mehr]
(
0
Bewertungen)
DGAP-News24.06.2014
Epigenomics AG: Epigenomics AG Announces Publication of Results of Two U.S. Clinical Studies with its Blood-based Epi proColon(R) CRC Screening Test
...Studies with its Blood-based Epi proColon(R) CRC Screening Test 24.06.2014 / 09:00 --------------------------------------------------------------------- Berlin (Germany), Germantown, MD (U.S.A.), June 24, 2014 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that results from its U.S. clinical validation study for its blood-based colorectal cancer (CRC) detection test Epi proColon(R) as well as from its... [mehr]
(
0
Bewertungen)
08.01.2018
Parker Aerospace Opens Second Global Customer Response Center (CRC) in Singapore
...first global CRC opened in Irvine, California, in October 2015. The new Singapore CRC is designed to work in conjunction with the Irvine-based CRC, where only one CRC will be active at any one time in a “follow the sun” strategy. Today, Parker’s customers worldwide can contact either of the customer response centers using the same phone numbers, email, or live chat at any time: Customer service: +1 (949) 809-8200 Dedicated AOG: +1 (949) 851-4357 Email: CRC@parker.com Live... [mehr]
(
0
Bewertungen)
30.09.2019
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI (encorafenib), MEKTOVI (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in... [mehr]
(
0
Bewertungen)
04.06.2016
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
...regimens for the BRAF-mutant mCRC population; the results of the BEACON CRC trial will hopefully provide us with the prospective information we need to take us one step closer to achieving that goal." Colorectal cancer (CRC) is one of the most challenging types of cancers, with an estimated 10 percent of CRCs associated with an oncogenic mutation in the BRAF gene.[1] Studies have observed that patients with BRAF-mutant mCRC have shorter progression-free survival and overall... [mehr]
(
0
Bewertungen)
DGAP-News22.07.2013
Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
...CRC screening could save lives and be health-economically beneficial 22.07.2013 / 10:30 --------------------------------------------------------------------- Press release Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial - CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates - Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC... [mehr]
(
0
Bewertungen)
DGAP-News24.06.2014
Epigenomics AG: Epigenomics AG Announces Publication of Results of Two U.S. Clinical Studies with its Blood-based Epi proColon(R) CRC Screening Test
...Studies with its Blood-based Epi proColon(R) CRC Screening Test 24.06.2014 / 09:00 --------------------------------------------------------------------- Berlin (Germany), Germantown, MD (U.S.A.), June 24, 2014 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that results from its U.S. clinical validation study for its blood-based colorectal cancer (CRC) detection test Epi proColon(R) as well as from its... [mehr]
(
0
Bewertungen)
08.01.2018
Parker Aerospace Opens Second Global Customer Response Center (CRC) in Singapore
...first global CRC opened in Irvine, California, in October 2015. The new Singapore CRC is designed to work in conjunction with the Irvine-based CRC, where only one CRC will be active at any one time in a “follow the sun” strategy. Today, Parker’s customers worldwide can contact either of the customer response centers using the same phone numbers, email, or live chat at any time: Customer service: +1 (949) 809-8200 Dedicated AOG: +1 (949) 851-4357 Email: CRC@parker.com Live... [mehr]
(
0
Bewertungen)
30.09.2019
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI (encorafenib), MEKTOVI (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in... [mehr]
(
0
Bewertungen)
04.06.2016
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
...regimens for the BRAF-mutant mCRC population; the results of the BEACON CRC trial will hopefully provide us with the prospective information we need to take us one step closer to achieving that goal." Colorectal cancer (CRC) is one of the most challenging types of cancers, with an estimated 10 percent of CRCs associated with an oncogenic mutation in the BRAF gene.[1] Studies have observed that patients with BRAF-mutant mCRC have shorter progression-free survival and overall... [mehr]
(
0
Bewertungen)

Diskussionen zu "CRC"

Bluttest - Krebserkennung - ValitionRX - Da geht was..?!09.06.2019
...is Epigenomics, Exact Sciences, Grail, Applied Proteomics, and a handful of small, private companies. Epigenomics is probably the company with a product most similar to ours (a blood based ELISA test for CRC) but we are demonstrating higher sensitivity (accuracy), better early stage CRC detection, better polyp detection, and we require much less blood for our analysis. Exact has a higher priced fecal based test that is selling well in the US, but almost certainly patients would prefer a blood... [mehr]
(
2
Empfehlungen)
Ein neuer SUPER-TREND! FYI Resources LTD WKN: A0RDPF15.04.2019
...of the Battery Technology CRC, FYI have submitted key R&D project recommendations suitable to the CRC mandate that will benefit the battery industry and FYI us immensely in the development of our Cadoux HPA project. The concept is that if our project proposals are accepted, Phd students, a project manager and budgeted funds will be directed at our R&D project - with oversight from FYI. The CRC development is a positive for FYI as we progress our HPA strategy as it leads into our planned alumina... [mehr]
(
3
Empfehlungen)
Ein neuer SUPER-TREND! FYI Resources LTD WKN: A0RDPF15.04.2019
...of the Battery Technology CRC, FYI have submitted key R&D project recommendations suitable to the CRC mandate that will benefit the battery industry and FYI us immensely in the development of our Cadoux HPA project. The concept is that if our project proposals are accepted, Phd students, a project manager and budgeted funds will be directed at our R&D project - with oversight from FYI. The CRC development is a positive for FYI as we progress our HPA strategy as it leads into our planned alumina... [mehr]
(
1
Empfehlung)
Array BioPharma....ein Übernahmekandidat?15.01.2019
...in up to 15% of all patients with mCRC and V600 is the most common BRAF mutation. [1-5] BRAFV600E-mutant mCRC patients have a mortality risk more than double that of mCRC patients without the mutation, and currently there are no U.S. Food and Drug Administration (FDA)-approved therapies specifically indicated for this high unmet need population. [3-10] "The mature median overall survival of 15.3 months demonstrated in the safety lead-in of the BEACON CRC trial is unprecedented in this patient... [mehr]
(
0
Empfehlungen)
___MOLOGEN AG__Dabeisein ist Alles__Jetzt gehts richtig los_03.11.2018
...TLR9-targeted immunoactivation with MGN1703 in maintenance therapy of metastatic CRC after an effective first-line regimen inducing a tumour response. It is important, however, that the current results are not over-interpreted because of the very limited sample size due to the early study termination. A randomised, phase III trial of MGN1703 in the first-line/maintenance setting in patients with metastatic CRC is planned. Insgesamt sind die Ergebnisse dieser Studie ermutigend und deuten auf... [mehr]
(
5
Empfehlungen)
UTSTARCOM( UTSI )!15.08.2001
...perfect cutting-edge solution for their needs.`` Wu added, ``CRC is planning to deploy 15 million lines of local access network by the end of 2001; we believe that PAS(TM) will definitely help them to achieve this goal.`` Using UTStarcom`s PAS(TM) system, CRC can combine its fixed-line resources with the wireless access and mobility functions, offering customers 64 Kbps data services in addition to regular mobile voice services. CRC`s network covers 65,000 miles of railways throughout Mainland.... [mehr]
(
0
Empfehlungen)
Portal Software - Super Wert mit tollem Chart!27.06.2000
...Shanghai Online, Xinjiang, Chongging Online, Liaoning and Jilin. CRC already provides an internal communications service for the entire national railway network. With Infranet, CRC plans to roll-out this extensive IP network to the public, potentially supporting more than three million users in 30 cities. As CRC`s business grows, its capacity can be easily expanded to more than ten million users. Impressed with Infranet`s reliable performance flexibility and scalability, CRC selected... [mehr]
(
0
Empfehlungen)
UTSTARCOM( UTSI )!16.01.2002
...operator in China. Originally the largest private communications network serving China`s railway system, CRC was officially founded on December 26, 2000 after internal structure reform. CRC`s telecom services include local fixed-line, long distance, data service, IP telephony and satellite services by both wireline and wireless access. According to published reports by CRC, they have set a goal of 15-30 million fixed-line subscribers by the end of 2005. About UTStarcom, Inc. UTStarcom designs,... [mehr]
(
0
Empfehlungen)
Portal Software27.06.2000
...Shanghai Online, Xinjiang, Chongging Online, Liaoning and Jilin. CRC already provides an internal communications service for the entire national railway network. With Infranet, CRC plans to roll-out this extensive IP network to the public, potentially supporting more than three million users in 30 cities. As CRC`s business grows, its capacity can be easily expanded to more than ten million users. Impressed with Infranet`s reliable performance flexibility and scalability, CRC selected Portal`s... [mehr]
(
0
Empfehlungen)
GPC - Chancen und Risiken22.04.2009
...colorectal cancer (CRC). Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin (FOLPI) as a first-line option for CRC. Based on the safety data as well as the promising clinical activity observed in this trial, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed... [mehr]
(
0
Empfehlungen)
UTSTARCOM( UTSI )!15.08.2001
...perfect cutting-edge solution for their needs.`` Wu added, ``CRC is planning to deploy 15 million lines of local access network by the end of 2001; we believe that PAS(TM) will definitely help them to achieve this goal.`` Using UTStarcom`s PAS(TM) system, CRC can combine its fixed-line resources with the wireless access and mobility functions, offering customers 64 Kbps data services in addition to regular mobile voice services. CRC`s network covers 65,000 miles of railways throughout Mainland.... [mehr]
(
0
Empfehlungen)
Portal Software - Super Wert mit tollem Chart!27.06.2000
...Shanghai Online, Xinjiang, Chongging Online, Liaoning and Jilin. CRC already provides an internal communications service for the entire national railway network. With Infranet, CRC plans to roll-out this extensive IP network to the public, potentially supporting more than three million users in 30 cities. As CRC`s business grows, its capacity can be easily expanded to more than ten million users. Impressed with Infranet`s reliable performance flexibility and scalability, CRC selected... [mehr]
(
0
Empfehlungen)
UTSTARCOM( UTSI )!16.01.2002
...operator in China. Originally the largest private communications network serving China`s railway system, CRC was officially founded on December 26, 2000 after internal structure reform. CRC`s telecom services include local fixed-line, long distance, data service, IP telephony and satellite services by both wireline and wireless access. According to published reports by CRC, they have set a goal of 15-30 million fixed-line subscribers by the end of 2005. About UTStarcom, Inc. UTStarcom designs,... [mehr]
(
0
Empfehlungen)
Portal Software27.06.2000
...Shanghai Online, Xinjiang, Chongging Online, Liaoning and Jilin. CRC already provides an internal communications service for the entire national railway network. With Infranet, CRC plans to roll-out this extensive IP network to the public, potentially supporting more than three million users in 30 cities. As CRC`s business grows, its capacity can be easily expanded to more than ten million users. Impressed with Infranet`s reliable performance flexibility and scalability, CRC selected Portal`s... [mehr]
(
0
Empfehlungen)
GPC - Chancen und Risiken22.04.2009
...colorectal cancer (CRC). Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin (FOLPI) as a first-line option for CRC. Based on the safety data as well as the promising clinical activity observed in this trial, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed... [mehr]
(
0
Empfehlungen)